Spots Global Cancer Trial Database for zoledronic acid
Every month we try and update this database with for zoledronic acid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid | NCT00172029 | Breast Cancer W... | Zoledronic acid | 18 Years - | Novartis | |
| Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases | NCT00079001 | Metastatic Canc... Prostate Cancer | zoledronic acid placebo androgen depriv... GnRH agonist Calcium supplem... Vitamin D | 18 Years - | Alliance for Clinical Trials in Oncology | |
| The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss | NCT00375505 | Breast Cancer | Zoledronic acid Placebo | 18 Years - | Novartis | |
| Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density | NCT00114270 | Breast Cancer Osteoporosis | letrozole zoledronic acid | 18 Years - | National Cancer Institute (NCI) | |
| Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) | NCT01204203 | Mesothelioma | Zometa | 19 Years - | University of Alabama at Birmingham | |
| Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Lung Cancer | NCT02622607 | Lung Cancer | Zoledronic acid | 18 Years - 70 Years | Tang-Du Hospital | |
| Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid | NCT00172029 | Breast Cancer W... | Zoledronic acid | 18 Years - | Novartis | |
| Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma | NCT03932071 | Lung Metastases Tumor Necrosis | Zoledronic Acid | - | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer | NCT00039104 | Adenocarcinoma ... Recurrent Prost... Stage IV Prosta... | rebimastat zoledronic acid laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | NCT03295981 | Giant Cell Tumo... | Zoledronic Acid | 18 Years - | St. Louis University | |
| Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer | NCT02595138 | Triple Negative... | Zoledronic acid | 18 Years - | ChineseAMS | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients | NCT03336983 | Prostate Cancer Bone Metastases | Zoledronic Acid Enzalutamide | 18 Years - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | |
| Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease | NCT00558272 | Breast Cancer Prostate Cancer Bone Neoplasms | AZD0530 Zoledronic Acid | 18 Years - | AstraZeneca | |
| THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | NCT01341262 | Multiple Myelom... | Thalidomide Dexamethasone Zoledronic acid Cyclophosphamid... Melphalan | 18 Years - 65 Years | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| Prolonged Protection From Bone Disease in Multiple Myeloma | NCT02286830 | Multiple Myelom... | Zoledronic acid | 18 Years - | Odense University Hospital | |
| S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. | NCT00127205 | Breast Cancer | clodronate diso... ibandronate sod... zoledronic acid | 18 Years - | SWOG Cancer Research Network | |
| Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases | NCT00242554 | Prostate Cancer | Zoledronic acid | 18 Years - 80 Years | Novartis | |
| Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer | NCT00966992 | Uterine Cervica... | Zoledronic acid | 18 Years - | Washington University School of Medicine | |
| A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates | NCT00172016 | Prostate Cancer... | Zoledronic acid | 18 Years - | Novartis | |
| Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | NCT00215943 | Multiple Myelom... | zoledronic acid dexamethasone thalidomide vincristine adriamycin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid | NCT01409811 | Estrogen Recept... Invasive Ductal... Progesterone Re... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... | zoledronic acid laboratory biom... therapeutic con... | - | City of Hope Medical Center | |
| Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole | NCT00376740 | Breast Cancer | zoledronic acid | 18 Years - 82 Years | Soroka University Medical Center | |
| Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases | NCT00081159 | Metastatic Canc... Prostate Cancer | Doxorubicin hyd... Goserelin aceta... Leuprolide acet... Zoledronic acid orchiectomy strontium chlor... | - | M.D. Anderson Cancer Center | |
| Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC | NCT01062503 | Metastatic Pros... Bone Metastasis | Zoledronic acid | 18 Years - | University Health Network, Toronto | |
| Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis | NCT00237159 | Prostate Cancer... | Zoledronic acid | 18 Years - | Novartis | |
| A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients | NCT00741377 | Multiple Myelom... | BHQ880 Zoledronic acid | 18 Years - 78 Years | Novartis | |
| Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial | NCT03173976 | Chondrosarcoma | Zoledronic Acid | 18 Years - | University of Iowa | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC) | NCT00172042 | Non-Small-Cell ... | Zoledronic acid... | 18 Years - | Novartis | |
| Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer | NCT00226954 | Urologic Neopla... | zoledronic acid | 18 Years - | Stanford University | |
| Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases | NCT03951493 | Vertebral Metas... | Zoledronic Acid... Hypo-fractured ... | 18 Years - | Institut Cancerologie de l'Ouest | |
| Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer | NCT00391690 | Prostate Cancer | Zoledronic acid | 18 Years - | Novartis | |
| Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone | NCT02516423 | Solitary Osseou... | ixazomib lenalidomide dexamethasone zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307 | NCT00873808 | Breast Cancer | clodronate diso... demeclocycline ... ibandronate sod... tetracycline hy... zoledronic acid laboratory biom... adjuvant therap... computed tomogr... dual x-ray abso... | 18 Years - | SWOG Cancer Research Network | |
| Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year | NCT00424983 | Multiple Myelom... Breast Cancer | Zoledronic acid | 18 Years - 75 Years | Novartis | |
| Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates | NCT00577642 | Multiple Myelom... | Zoledronic acid | 18 Years - | Massachusetts General Hospital | |
| Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases | NCT00079001 | Metastatic Canc... Prostate Cancer | zoledronic acid placebo androgen depriv... GnRH agonist Calcium supplem... Vitamin D | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer | NCT00892242 | Adenocarcinoma | Zoledronic acid | 18 Years - | Washington University School of Medicine | |
| Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma | NCT00742924 | Sarcoma | cisplatin dexrazoxane hyd... doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate zoledronic acid adjuvant therap... neoadjuvant the... therapeutic con... filgrastim Mesna | - 40 Years | Children's Oncology Group | |
| Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer | NCT00326820 | Breast Cancer Hypercalcemia o... Metastatic Canc... | ibandronate sod... zoledronic acid Zolendronic Aci... | 18 Years - | Wales Cancer Trials Unit | |
| Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases | NCT00242554 | Prostate Cancer | Zoledronic acid | 18 Years - 80 Years | Novartis | |
| Study on Bisphosphonates Targeting Triple-negative Breast Cancer | NCT04045522 | Breast Cancer | Zoledronic Acid | 55 Years - 70 Years | Shengjing Hospital | |
| Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases | NCT00060138 | Breast Cancer Hypercalcemia o... Metastatic Canc... Pain | monoclonal anti... zoledronic acid | 18 Years - | Chugai Pharmaceutical | |
| Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only | NCT00950911 | Bone Metastases... Bone Metastases... Bone Metastases... | amg 162 | 18 Years - | Amgen | |
| Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma | NCT01404702 | Neuroblastoma | Zoledronic Acid Aldesleukin | 2 Years - 21 Years | University of Alabama at Birmingham | |
| Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) | NCT00889590 | Giant Cell Tumo... Osteoclastoma | Zoledronic acid | 18 Years - | Leiden University Medical Center | |
| Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer | NCT00436917 | Breast Cancer Osteoporosis | zoledronic acid Letrozole as ad... | 18 Years - 120 Years | Mayo Clinic | |
| N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma | NCT00885326 | Neuroblastoma | Bevacizumab cyclophosphamid... zoledronic acid | - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms | NCT01194440 | Ductal Carcinom... Estrogen Recept... Progesterone Re... Stage I Breast ... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | letrozole zoledronic acid | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders | NCT00258258 | Multiple Myelom... | paricalcitol zoledronic acid | 18 Years - | Roswell Park Cancer Institute | |
| Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study | NCT02632903 | Osteoporosis Osteonecrosis Acute Lymphobla... | Zoledronic acid | 8 Years - 16 Years | Children's Hospital of Eastern Ontario | |
| The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy | NCT00063609 | Prostate Cancer | zoledronic acid | 18 Years - | Novartis | |
| Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer | NCT00375648 | Pain | Zoledronic acid | 18 Years - | Novartis | |
| Study in Localized and Disseminated Ewing Sarcoma | NCT00987636 | Ewing's Sarcoma | Zoledronic acid Busulfan Treosulfan | 48 Months - 50 Years | University Hospital Muenster | |
| Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer | NCT00022087 | Breast Cancer Osteoporosis | calcium salts cholecalciferol zoledronic acid | 40 Years - | Alliance for Clinical Trials in Oncology | |
| Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases | NCT00434317 | Neoplasm Metast... | Zoledronic acid | 18 Years - | Novartis | |
| Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer | NCT00391690 | Prostate Cancer | Zoledronic acid | 18 Years - | Novartis | |
| Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions | NCT00375427 | Breast Cancer W... | Zoledronic acid | 18 Years - | Novartis | |
| Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer | NCT00295867 | Breast Cancer | Zoledronic Acid | 18 Years - | University of California, San Francisco | |
| Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer | NCT00242567 | Prostate Cancer | Zoledronic Acid Androgen Depriv... | 18 Years - | Novartis | |
| Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer | NCT00049452 | Breast Cancer Osteoporosis | zoledronic acid | 18 Years - 50 Years | National Cancer Institute (NCI) | |
| Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases | NCT00434447 | Bone Neoplasms | Zoledronic acid | 18 Years - | Novartis | |
| Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions | NCT00130494 | Breast Cancer Neoplasm Metast... | Zoledronic acid | 18 Years - 70 Years | Spanish Breast Cancer Research Group | |
| Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma | NCT00691236 | Osteosarcoma | Zoledronic acid Standard chemot... | 18 Years - 65 Years | Tata Memorial Hospital | |
| Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms | NCT00005073 | Prostate Cancer | zoledronic acid | 18 Years - | Novartis | |
| Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain | NCT00482378 | Multiple Myelom... Pain | Pamidronate Zoledronic acid Sm 153 lexidron... | 18 Years - 120 Years | Mayo Clinic | |
| A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid | NCT06221072 | Imaging Examina... | JMT103 zoledronic acid | 18 Years - | Shanghai JMT-Bio Inc. | |
| Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis | NCT00172003 | Renal Cell Canc... Neoplasm Metast... | Zoledronic acid | 18 Years - | Novartis | |
| Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases | NCT00434317 | Neoplasm Metast... | Zoledronic acid | 18 Years - | Novartis | |
| RADAR Trial - Randomised Androgen Deprivation and Radiotherapy | NCT00193856 | Prostate Cancer | Leuprorelin Ace... Zoledronic Acid Conventional ex... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| A Multiple Myeloma Trial in Patients With Bone Metastases | NCT00104104 | Multiple Myelom... | zoledronic acid | 18 Years - | Novartis | |
| Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy | NCT00237146 | Prostate Cancer | Zoledronic acid | 18 Years - | Novartis | |
| Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer | NCT00436917 | Breast Cancer Osteoporosis | zoledronic acid Letrozole as ad... | 18 Years - 120 Years | Mayo Clinic | |
| A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC) | NCT00172042 | Non-Small-Cell ... | Zoledronic acid... | 18 Years - | Novartis | |
| ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer | NCT00415779 | Metastatic Pros... | docetaxel zoledronic acid | 18 Years - | National Cancer Institute, Naples | |
| Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC | NCT01259193 | Hepatocellular ... | Sorafenib and Z... | 18 Years - 80 Years | Fudan University | |
| A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates | NCT00172016 | Prostate Cancer... | Zoledronic acid | 18 Years - | Novartis | |
| Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions | NCT00130494 | Breast Cancer Neoplasm Metast... | Zoledronic acid | 18 Years - 70 Years | Spanish Breast Cancer Research Group | |
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | NCT00295646 | Breast Cancer | tamoxifen anastrozole zoledronic acid goserelin | 19 Years - 59 Years | Austrian Breast & Colorectal Cancer Study Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
